Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China
Cancer · 2024-09 · 130 (S17) · 3054-3066
DOI: 10.1002/cncr.35475 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 02.08.2024. Verfasst von Chunwei Xu und 51 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Lung Diseases, Interstitial, Immunoconjugates. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Zhejiang Traditional Chinese Medicine Science Fund Project, National Natural Science Foundation of China of Zhejiang Cancer Hospital Cultivation Project, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) have demonstrated effectiveness in treating various cancers, particularly exhibiting specificity in targeting human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. Recent advancements in phase 3 clinical trials have broadened current understanding of ADCs, especially trastuzumab deruxtecan, in treating other HER2‐expressing malignancies. This expansion of knowledge has led to the US Food and Drug Administration's approval of trastuzumab deruxtecan for HER2‐positive and HER2‐low breast cancer, HER2‐positive gastric cancer, and HER2‐mutant nonsmall cell lung cancer. Concurrent with the increasing use of ADCs in oncology, there is growing concern among health care professionals regarding the rise in the incidence of interstitial lung disease or pneumonitis (ILD/p), which is associated with anti‐HER2 ADC therapy. Studies on anti‐HER2 ADCs have reported varying ILD/p mortality rates. Consequently, it is crucial to establish guidelines for the diagnosis and management of ILD/p in patients receiving anti‐HER2 ADC therapy. To this end, a panel of Chinese experts was convened to formulate a strategic approach for the identification and management of ILD/p in patients treated with anti‐HER2 ADC therapy. This report presents the expert panel's opinions and recommendations, which are intended to guide the management of ILD/p induced by anti‐HER2 ADC therapy in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
- Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
- Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
- Department of Breast Cancer Internal Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
- Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.
ORCID-Profile: Yiding Chen, Wenxian Wang, Wenzhao Zhong, Hongbing Liu, Liyun Miao, Jianya Zhou
Förderung
- Zhejiang Traditional Chinese Medicine Science Fund Project
- National Natural Science Foundation of China of Zhejiang Cancer Hospital Cultivation Project
- Natural Science Foundation of Zhejiang Province
- Xisike-Hengrui Cancer Research Foundation
- China Postdoctoral Science Foundation
- Medical Scientific Research Foundation of Zhejiang Province, China
Zitieren
APA
Xu, C., Chen, Z., Xia, Y., Shi, Y., Fu, P., Chen, Y., Wang, X., Zhang, L., Li, H., Chen, W., Fu, J., Huang, L., Shu, J., Wang, O., Wu, W., Xie, B., Wang, T., Zhang, W., Shen, S., …, & Wang, X. (2024). Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China. Cancer, 130(S17), 3054-3066. https://doi.org/10.1002/cncr.35475
Vancouver
Xu C, Chen Z, Xia Y, Shi Y, Fu P, Chen Y, et al. Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China. Cancer. 2024;130(S17):3054-3066. doi:10.1002/cncr.35475
BibTeX
@article{Xu2024,
author = {Xu, Chunwei and Chen, Zhanhong and Xia, Yuanli and Shi, Yanxia and Fu, Peifen and Chen, Yiding and Wang, Xian and Zhang, Lili and Li, Hengyu and Chen, Wenyan and Fu, Jianfei and Huang, Liming and Shu, Jingde and Wang, Ouchen and Wu, Weizhu and Xie, Bojian and Wang, Ting and Zhang, Weiping and Shen, Shurong and Li, Qun and Luo, Ting and Zhang, Bin and Xie, Yanru and Wang, Hongxia and Wang, Qian and Wang, Wenxian and Li, Ziming and Song, Zhengbo and Fang, Wenfeng and Zhong, Wenzhao and Zhang, Yongchang and Zhan, Ping and Liu, Hongbing and Lv, Tangfeng and Miao, Liyun and Min, Lingfeng and Wang, Feng and Meng, Rui and Zhu, Youcai and Wang, Lin and Wan, Bing and Wang, Dong and Hao, Yue and Zhou, Jianya and Huang, Long and Zhang, Zhang and Lv, Donglai and Fang, Meiyu and Lu, Yuanzhi and Si, Lu and Song, Yong and Wang, Xiaojia},
title = {Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody‐drug conjugates–induced interstitial lung disease/pneumonitis: An expert consensus in China},
journal = {Cancer},
year = {2024},
volume = {130},
number = {S17},
pages = {3054--3066},
doi = {10.1002/cncr.35475}
}
EUVIMED